Geometrically enhanced differential immunocapture (GEDI) and an antibody for prostate-specific membrane antigen (PSMA) are used for high-efficiency and high-purity capture of prostate circulating tumor cells from peripheral whole blood samples of castrate-resistant prostate cancer patients.
Prostate cancer circulating tumor cells (PCTCs) are often found in the blood of patients suffering from metastatic prostate cancer.
1,2
While these PCTCs are rare, as few as one cell per 10 9 hematologic cells in blood, 3, 4 they are theorized to contribute to metastatic progression. 3, 5 Currently, the enumeration of PCTCs is used clinically as a prognostic indicator of patient survival. 2, 6, 7 Capture of peripheral blood PCTCs may enable early clinical assessment of metastatic process and chemotherapeutic response, as well as genetic and pharmacological evaluation of cancer cells.
Current approaches to isolate circulating tumor cells are complex and produce low yields and purity. 5 Existing commercial and research devices for the immunocapture of rare cancer cells use EpCAM antibodies, 2, 8, 9 which capture many circulating endothelial cells and large numbers of leukocytes. As a result, purity of captured cells is widely variable and often below 50%. In addition, while previous devices use 3D antibody-coated surfaces for immunocapture, 8, 9 these devices are not designed to induce a size-dependent collision frequency. Devices focused on size-dependent particle transport are typically focused on sorting, 10 separation, 11,12 or filtration.
13
In this communication, we demonstrate high-efficiency and high-purity capture of PCTCs from peripheral blood samples of castrate-resistant prostate cancer patients using an antibody for prostate-specific membrane antigen (PSMA), a highly prostatespecific cell-surface antigen.
14 In addition, we describe a theoretical framework for the use of staggered obstacle arrays to create sizedependent particle trajectories that maximize PCTC-wall interactions while minimizing the interactions of other blood cells. We term this technique geometrically enhanced differential immunocapture (GEDI). Glass and silicon devices were fabricated and chemically functionalized to localize a monoclonal antibody (J591) that has high binding avidity to and specificity for epitopes on the extracellular PSMA domain 15 and minimal nonspecific binding with PSMA negative cells. Cell capture efficiency and purity were determined via capture of cultured prostate cancer cell populations spiked in PBS and in whole blood and capture of PCTCs from patient blood samples.
Prior to cell capture, 2D experiments were conducted to determine capture specificity of the surface immobilized immunochemistry to PSMA expressing cells. Glass coverslips were functionalized with an amine-terminated surface via a two-step process using 4% (v . Following the 15 min incubation, the coverslips were gently rinsed and imaged using a microscope. Capture specificity for PSMA+ cells was verified by counting 20 distinct observation areas with 15 AE 3 LNCaPs captured per field compared with 1 AE 0.5 PC3 and 2 AE 1 PBMCs (Fig. S1, ESI †) .
The GEDI mdevice geometry was designed to maximize streamline distortion and thus bring desired cells in contact with the immunocoated obstacle walls for capture. Blood is a dense heterogeneous cell suspension consisting of cells of various sizes ranging from approximately 4 to 18 mm in size. 16 PCTCs, in contrast, are larger and range from 15 to 25 mm in diameter. 16 Relative obstacle alignment was chosen so that the displacement caused by cell impact with obstacles (which ranges from zero to one cell radius) increases the likelihood of future cell impacts for large cells more than for small cells. Thus when cell-obstacle impact does not lead to capture, larger cells are displaced onto streamlines that impinge onto the next obstacle, while smaller cells are displaced onto streamlines that do not impinge (Fig. 1A) . Cell advection was modeled in silico (computational details in the ESI †) to determine obstacle array geometries that optimize PCTC-wall interactions and minimize wall shear forces to maximize PCTC capture. For a given obstacle geometry, the frequency of cellwall collisions is a function of cell size (Fig. 1B) . Obstacle shape and/ or array geometries determine a tunable cell diameter threshold whereby larger cells have significantly more cell-wall collisions compared with smaller cells. This feature of the GEDI mdevice may increase cell capture population purity by decreasing opportunities for non-target blood cells to interact with immunocoated surfaces. The GEDI mdevice designs used in these studies consist of approximately 5000 circular or octagonal posts (80 mm diameter) in a 100 mm deep by 8 mm wide by 25 mm long channel. The posts form a regular array with 100 mm gaps and each subsequent row is shifted by 7 mm.
In order to characterize the GEDI mdevice performance, target cell capture efficiency and purity was determined for experiments using fluorescently labeled model prostate tumor cell populations (detailed cell handling methods in the ESI †). LNCaPs were fluorescently labeled with a standard cell labeling kit [Invitrogen, Eugene, OR], counted on a hemacytometer, and resuspended in either PBS supplemented with 1% bovine serum albumin (BSA) or whole blood from healthy donors at concentrations of 150-220 cells mL
À1
. The labeled cell suspensions were processed through the GEDI mdevice at 1 mL h À1 followed by a PBS rinse at the same flow rate for 10 min.
Captured cells were then enumerated by scanning the entire device area using fluorescence microscopy. The GEDI mdevices captured 97 AE 3% of the spiked LNCaP cells from PBS and 85 AE 5% from blood (Fig. 2) . In addition to performing with capture efficiencies from unprocessed whole blood that are approximately 40% higher than other one-step microfluidic immunoreactive devices, 8 the mdevice also captured a cell population from whole blood that was 68 AE 6% pure. The 37% increase in capture purity with the GEDI mdevice compared to similar capture methods may be attributed to the combined effects of using a high specificity mAb, J591, and the geometry of the GEDI mdevice.
Following performance validation, human PCTCs from whole peripheral blood samples of patients diagnosed with castrate-resistant prostate cancer were captured and enumerated. GEDI devices processed 1 mL samples of whole blood obtained under university IRB-approved protocols. The devices were rinsed with PBS for 10 min to remove unbound cells, and FITC-conjugated J591 was used to fluorescently label PSMA+ captured cells in situ. Cells were enumerated with a microscope as described above. While direct comparison of PCTC density and purity between individual patients is impossible due to the variability in individual patient cancer progression, PCTCs were found in 90% of samples tested (n ¼ 20) (Fig. 3B) . To assess the repeatability of the mdevice to capture native PCTCs from patients, one blood sample was well mixed and split into 4 aliquots of one millilitre each. Each aliquot was processed by different devices, with the number of captured PCTCs averaging 27 AE 4 cells and a capture purity of 62 AE 2% (Fig. 3A) . This constitutes a PCTC enrichment of approximately 10 9 as compared to the other cells in the system and demonstrates high reproducibility of PCTC capture from whole blood using J591 mAb and the current geometry.
In summary, this work describes a GEDI array functionalized with prostate-specific J591 mAb and demonstrates its use for the highefficiency capture of PCTCs from peripheral blood samples of castrate-resistant prostate cancer patients. Leveraging the fluid mechanical design to control cell transport combined with high antibody specificity to target cells has demonstrated both exceptionally high cell capture efficiencies and highly pure captured cell populations. Compared to reported work, 2,8 this approach yields a 40% improvement in both capture efficiency and capture purity producing significant enrichment of rare cell populations from unprocessed clinical whole blood samples. While the isolation of PCTCs has been demonstrated in these studies, the design of GEDI arrays can be applied to any transport problem that requires differential particle-surface interaction frequencies within heterogeneous-sized colloidal suspensions. Potential applications for the mdevices described herein include capture of PCTCs to study the molecular mechanisms of clinical drug resistance, profiling of individual patients' PCTCs in order to generate personalized chemotherapeutics, as well as real-time monitoring of chemotherapeutic efficacy using a non-invasive blood-based assay.
